Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7722108 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL1967676 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL18313954 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL585389 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL1975610 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL15151157 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL1975652 | 0.91 | CHRM2 (0.47) | CHRM2CHRM1CHRM3CYP3A4HSD17B10 | |
| SCHEMBL60188 | 0.88 | NR1H2 (0.42) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL14210999 | 0.88 | NR1H2 (0.42) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL18555624 | 0.88 | NR1H2 (0.42) | CHRM2CHRM1CHRM3CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023204308-A1 | OXAZEPINE DERIVATIVE | 帝人ファーマ株式会社 | 2023-10-26 | — | — | WO | disclosed |
| WO-2023017541-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYL PIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA MALEATE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-02-16 | — | — | WO | disclosed |
| EP-2170860-B9 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2170860-B9 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2170860-B1 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2170860-B1 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2167492-B1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI SCIENCE CO LTD (KR) | 2015-10-14 | — | — | EP | disclosed |
| EP-2185544-B1 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8846675-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8772492-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-07-08 | — | — | US | disclosed |
| WO-2009004427-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2008077555-A2 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1856095-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006090163-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-08-31 | — | — | WO | disclosed |
| US-6399629-B1 | PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY | MICROCIDE PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| EP-0805681-A4 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0805681-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022775-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | BOD1L1, H1-3, BRIX1 | CHRM2 458/4885CHRM1 486/4885CHRM3 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.